# US 2013/0259892 A1 · Strongly inactivated and still highly immunogenic vaccine and process of manufacturing thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2013/0259892 A1
- Document ID: US20130259892A1
- Status: Published application
- Kind: A1
- Application number: 13/992,092
- Filed: 2011-12-08
- Published: 2013-10-03
- Earliest claimed: 2010-12-08
- Inventors: Geraldine Grouard-Vogel; Olivier Dhellin; Bernard Fancet; Pierre Vandepapeliere
- Web page: https://patentgrep.com/patent/US20130259892A1

## CPC

- C07K 14/525: Tumour necrosis factor [TNF]
- A61K 39/0008: {Antigens related to auto-immune diseases; Preparations to induce self-tolerance}
- A61K 47/643: {Albumins, e.g. HSA, BSA, ovalbumin or a Keyhole Limpet Hemocyanin [KHL]}
- A61K 47/646: {the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines}
- A61P 1/04: for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A61P 7/00: Drugs for disorders of the blood or the extracellular fluid
- A61P 17/06: Antipsoriatics
- A61P 19/02: for joint disorders, e.g. arthritis, arthrosis
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 35/00: Antineoplastic agents
- A61K 2039/6081: {Albumin; Keyhole limpet haemocyanin [KLH]}
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

An immunogenic product includes TNFα coupled with KLH, wherein the TNFα is strongly inactivated, which means that the product shows less than 30% of cytolytic activity and/or an inactivation factor of more than 15000, in the conditions of TEST A. An emulsion and a vaccine including the product and methods for preparing the immunogenic product are also described.

## Claims

### Claim at position 1

1-19. (canceled)

### Claim 20

An immunogenic product comprising TNFα coupled with KLH, wherein the TNFα is strongly inactivated, which means that the product at a concentration of 100 ng/ml shows less than 30% of cytolytic activity and/or an inactivation factor of more than 15000, in the conditions of TEST A.

### Claim 21 (depends on 20)

The immunogenic product according to claim 20, wherein said product remains inactivated overtime, which means that the product at a concentration of 100 ng/ml shows less than 80% of cytolytic activity and/or an inactivation factor of more than 500, in the conditions of TEST B.

### Claim 22 (depends on 20)

The immunogenic product according to claim 20, wherein said product may comprise free TNFαhomopolymers of more than 300 kDa and when said product comprises free TNFαhomopolymers of more than 300 kDa, the percentage of free TNFαhomopolymers of more than 300 kDa is of less than 30% w/w of total TNFα as calculated in TEST C.

### Claim 23 (depends on 20)

The immunogenic product according to claim 20, wherein said product is lyophilized.

### Claim 24 (depends on 20)

An immunogenic emulsion comprising a product according to claim 20 and an oil and a surfactant or a mixture thereof; wherein the emulsion is a water-in-oil emulsion or an oil-in-water emulsion, and wherein the oil, the surfactant and/or the mixture of oil and surfactant are pharmaceutically acceptable excipients.

### Claim 25 (depends on 24)

The immunogenic emulsion according to claim 24, comprising a mixture of oil and surfactant which is an adjuvant, preferably ISA 51.

### Claim 26 (depends on 20)

A vaccine composition comprising animmunogenic product according to claim 20.

### Claim 27 (depends on 20)

A vaccine composition comprising an immunogenic emulsion comprising a product according to claim 20, an oil and a surfactant or a mixture thereof.

### Claim 28

A method for preparing a product comprising TNFα coupled with KLH, wherein the TNFα is strongly inactivated, which means that the product at a concentration of 100 ng/ml shows less than 30% of cytolytic activity in the conditions of TEST A, comprising the steps of:
a) mixing together (i) purified TNFα, (ii) purified Keyhole limpet hemocyanin and (iii) glutaraldehyde
b) removing compounds having a molecular weight of less than 10 kDa
characterized in that after step b) the following steps are performed:
c) adding formaldehyde in a concentration/time of reaction condition ranging from at least 60 mM for at least 240 hours to at least 120 mM for at least 144 hours
d) blocking the reaction with formaldehyde by adding a quenching compound selected from (i) a reducing agent and (ii) an amino acid selected from the group consisting of lysine and glycine and mixture thereof,
e) collecting said immunogenic product.

### Claim 29 (depends on 28)

The method according to claim 28, wherein in step a) glutaraldehyde is applied in a concentration of 1 to 50 mM for more than 110 to less than 400 minutes, preferably 25 mM for 240 minutes.

### Claim 30 (depends on 28)

The method according to claim 28, wherein in step c) formaldehyde is applied in a concentration of at least 200 mM during at least 240 hours, preferably of 220 to 270 mM for at least 300 hours.

### Claim 31 (depends on 28)

The method according to claim 28, wherein the reaction with glutaraldehyde is stopped by adding a quenching compound, preferably a quenching compound that is selected from (i) a reducing agent and (ii) an amino acid selected from the group consisting of lysine and glycine and mixture thereof.

### Claim 32 (depends on 28)

The method according to claim 28, wherein prior to collecting at step f), the substances having a molecular weight of less than 300 kDa are removed.

### Claim 33

A method for preparing a product comprising TNFα coupled with KLH, wherein the TNFα is strongly inactivated, which means that the product at a concentration of 100 ng/ml shows less than 30% of cytolytic activity in the conditions of TEST A, comprising the steps of:
a) mixing together (i) purified TNFα, (ii) purified Keyhole limpet hemocyanin and (iii) glutaraldehyde
b) removing compounds having a molecular weight of less than 10 kDa
c) adding formaldehyde in a concentration/time of reaction condition ranging from at least 60 mM for at least 144 hours to at least 250 mM for at least 96 hours,
characterized in that
in step a) glutaraldehyde is applied at a concentration of at least 20 mM during more than 18 hours, the reaction with glutaraldehyde is stopped by adding a quenching compound, preferably a quenching compound that is selected from (i) a reducing agent and (ii) an amino acid selected from the group consisting of lysine and glycine and mixture thereof, and then the product is collected.

### Claim 34 (depends on 33)

The method according to claim 33, wherein after step b) and prior to collecting the product, formaldehyde is applied in a concentration/time of reaction condition ranging from at least 250 mM for at least 4 days, and then the reaction with formaldehyde is blocked by adding a quenching compound selected from (i) a reducing agent and (ii) an amino acid selected from the group consisting of lysine and glycine and mixture thereof.

### Claim 35 (depends on 33)

The method according to claim 33, wherein prior to collecting the product, a step of tangential flow filtration using a filtration membrane having a cut-off value of at least 100 kDa. (pref 300 kDa) is performed.

### Claim 36 (depends on 27)

A method for treating a disease linked to an over-production of TNFαin a subject in need thereof, comprising administering to the subject a therapeutically amount of a vaccine according to claim 27.

### Claim 37 (depends on 28)

A method for treating a disease linked to an over-production of TNFαin a subject in need thereof, comprising administering to the subject a therapeutically amount of a vaccine according to claim 28.

### Claim 38 (depends on 36)

The method according to claim 36, wherein the disease linked to an over-production of TNFα is selected from the group consisting of ankylosingspondylitis, psoriasis, rhumatoid arthritis, Juvenile idiopathic arthritis, Inflammatory Bowel Disease, Crohn's disease, cachexia, and cancer.

### Claim 39

A kit comprising,
at least one vial containing an immunogenic product comprising TNFα coupled with KLH, wherein the TNFα is strongly inactivated, which means that the product at a concentration of 100 ng/ml shows less than 30% of cytolytic activity and/or an inactivation factor of more than 15000, in the conditions of TEST A,
at least one vial containing water for injection, and
at least one vial containing adjuvant,
and means for mixing the immunogenic product and the water in order to obtain an aqueous solution, and for contacting said solution to the adjuvant, and for emulsifying the mixture of the aqueous solution with the adjuvant, said kit further including at least one needle.

### Claim 40

A medical device comprising an immunogenic product comprising TNFα coupled with KLH, wherein the TNFα is strongly inactivated, which means that the product at a concentration of 100 ng/ml shows less than 30% of cytolytic activity and/or an inactivation factor of more than 15000, in the conditions of TEST A.

### Claim 41 (depends on 40)

The medical device according to claim 40, wherein the immunogenic product is comprised in an emulsion or in a vaccine composition.
